Vendor comparison · 2026
SS-31 vendors: 17 compared on COAs and price
Tissue & recoveryAlso known as Elamipretide, MTP-131, Bendavia
Evidence tier
Substantial published literature
463 publications over 21 years · trials not yet curated
- Vendors carrying it
- 17
- 15 with a listed price
- Vendors with checkable COAs
- 8
- 8 publish any certificate
- Lots tested
- 14
- 14 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- 18 Sept 2026
- oldest 17 Sept 2025
- Laboratories named
- 6
- most often Freedom Diagnostics Testing
- Median label gap
- 5.2%
- 50% of lots within 5% of label
- Median purity
- 99.87%
- 13 of 14 lots at 99% or above
- Lowest price per mg
- $3.00
- peer median $5.40
- Publications located
- 463
- researched since 2005
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
PeptidePlugs has the most checkable SS-31 testing in this index: 7 lots assayed by Freedom Diagnostics Testing, the newest on 1 Sept 2026. The lowest listed price is $3.00 per mg at Hydro Research Peptides, against a peer median of $5.40. 17 vendors carrying SS-31 are compared below. 8 publish at least one certificate naming a checkable laboratory, 14 lot records are on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying SS-31
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Origin LabsISO/IEC 17025 | 96.9100% | — | 1 / 1 | Freedom Diagnostics Testing | 100.0% | 34.6% | ||
| 2 | PeptidePlugs | 89.594% | $4.00 (74%) | 7 / 7 | Freedom Diagnostics Testing | 99.9% | 4.7% | ||
| 3 | Ascend ScienceISO/IEC 17025 | 8794% | $5.25 (97%) | 0 | — | — | — | — | |
| 4 | Hydro Research PeptidesISO/IEC 17025 | 85.689% | $3.00 (56%) | 0 | — | — | — | — | no reportVisit site |
| 5 | One Aminos | 85.189% | $4.50 (83%) | 1 / 1 | United Laboratories | 99.6% | 11.5% | ||
| 6 | NeuroLabs Research | 80.891% | $5.40 (100%) | 0 | — | — | — | — | no reportVisit site |
| 7 | Northline LabsISO/IEC 17025 | 79.395% | $6.00 (111%) | 1 / 1 | ILS Laboratories | 99.6% | 4.7% | ||
| 8 | Koi PeptidesAge-gated COAs | 77.992% | $5.00 (93%) | 0 | — | — | — | — | no reportVisit site |
| 9 | Evolve Peptides | 72.468% | $3.40 (63%) | 0 | — | — | — | — | no reportVisit site |
| 10 | Ascension Peptides | 71.889% | $8.00 (148%) | 1 / 1 | MZ Biolabs | 99.5% | 0.5% | ||
| 11 | Bench Grade Peptides | 71.189% | $8.00 (148%) | 1 / 1 | AV Analytics | 99.8% | 1.8% | ||
| 12 | Good Science Bio | 67.171% | $5.50 (102%) | 0 | — | — | — | — | no reportVisit site |
| 13 | True Research Labs | 6468% | $5.40 (100%) | 0 | — | — | — | — | no reportVisit site |
| 14 | Licensed Peptides | 60.687% | $10.00 (185%) | 1 / 1 | Vanguard Laboratory | 98.8% | 38.2% | ||
| 15 | Vertex Labs | 56.172% | — | 1 / 1 | Freedom Diagnostics Testing | 99.8% | 19.7% | ||
| 16 | Mile High Compounds | 54.691% | $7.00 (130%) | 0 | — | — | — | — | no reportVisit site |
| 17 | Sports Technology LabsAge-gated COAs | 54.171% | $8.00 (148%) | 0 | — | — | — | — | no reportVisit site |
Independent assays
No independently commissioned assay of SS-31 is on file. All 14 records below were published by the vendor that sells the product, naming the laboratory shown. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
What the certificates show
13 of 14 lots at 99% or above; median 99.87%.
| Range | lots |
|---|---|
| <95% | 0 |
| 95–97% | 0 |
| 97–98% | 0 |
| 98–99% | 1 |
| 99–99.5% | 0 |
| ≥99.5% | 13 |
50% of lots within 5% of the labelled mass; median gap 5.2%.
| Range | lots |
|---|---|
| ≤2% | 3 |
| 2–5% | 4 |
| 5–10% | 3 |
| 10–20% | 2 |
| >20% | 2 |
15 vendors, $3.00 to $10.00; median $5.40.
| Range | vendors |
|---|---|
| $2.00–$4.00 | 2 |
| $4.00–$6.00 | 7 |
| $6.00–$8.00 | 2 |
| $8.00–$10.00 | 4 |
Purity and mass are read from each certificate as published; the label gap is |labeled − assayed| ÷ labeled. Every value behind these bars is in the certificate table below.
Laboratories used
| Laboratory | Lots | Vendors | Share | Verify |
|---|---|---|---|---|
| Freedom Diagnostics TestingUS | 9 | 3 | 64% | Public lookup |
| AV Analytics | 1 | 1 | 7% | No public lookup found |
| ILS LaboratoriesUS | 1 | 1 | 7% | Public lookup |
| MZ BiolabsUS | 1 | 1 | 7% | No public lookup found |
| United LaboratoriesIN | 1 | 1 | 7% | Public lookup |
| Vanguard LaboratoryUS | 1 | 1 | 7% | No public lookup found |
Every certificate record
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2005 — 21 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
463 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.7% across 14 certificates
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
±0.29 pts purity across lots, mean label deviation 10.3%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
17 of 17 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
14 of 14 certificates from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is SS-31?
A mitochondria-targeted tetrapeptide (also known as elamipretide) studied for its effects on mitochondrial function and cellular energy.
Studied in published research for mitochondrial function and tissue protection.
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
Studied in animal models and human trials of mitochondrial and cardiac disease. PepIndex does not evaluate clinical significance and does not describe administration.
- Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice — Journal of neuroinflammation (2019)
Peer-reviewed article indexed in PubMed, published in Journal of neuroinflammation (2019).
- SS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting — Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2025)
Peer-reviewed article indexed in PubMed, published in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2025).
- Potential Therapeutic Candidates for Age-Related Macular Degeneration (AMD) — Cells (2021)
Peer-reviewed article indexed in PubMed, published in Cells (2021).
- Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model — Circulation. Heart failure (2026)
Peer-reviewed article indexed in PubMed, published in Circulation. Heart failure (2026).
- Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential — International journal of molecular sciences (2025)
Peer-reviewed article indexed in PubMed, published in International journal of molecular sciences (2025).
- Mitochondrial Dysfunction: The Silent Catalyst of Kidney Disease Progression — Cells (2025)
Peer-reviewed article indexed in PubMed, published in Cells (2025).
- Mitochondrial protein interaction landscape of SS-31 — Proceedings of the National Academy of Sciences of the United States of America (2020)
Peer-reviewed article indexed in PubMed, published in Proceedings of the National Academy of Sciences of the United States of America (2020).
- Elamipretide(SS-31) Attenuates Idiopathic Pulmonary Fibrosis by Inhibiting the Nrf2-Dependent NLRP3 Inflammasome in Macrophages — Antioxidants (Basel, Switzerland) (2023)
Peer-reviewed article indexed in PubMed, published in Antioxidants (Basel, Switzerland) (2023).
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.